Pages
Products
Synapsin-mCherry Lentivirus

Synapsin-mCherry Lentivirus

Cat.No. :  LV00964Z

Titer: ≥1*10^7 TU/mL / ≥1*10^8 TU/mL / ≥1*10^9 TU/mL Size: 100 ul/500 ul/1 mL

Storage:  -80℃ Shipping:  Frozen on dry ice

Inquire for Price

Lentivirus Particle Information

Quality Control

Cat. No. LV00964Z
Description This lentivirus contains mCherry under the control of human synapsin promoter.
Target Gene mCherry
Titer Varies lot by lot, for example, ≥1*10^7 TU/mL, ≥1*10^8 TU/mL, ≥1*10^9 TU/mL etc.
Size Varies lot by lot, for example, 100 ul, 500 ul, 1 mL etc.
Storage Store at -80℃. Avoid multiple freeze/thaw cycles.
Shipping Frozen on dry ice
Creative Biogene ensures high-quality lentivirus particles by optimizing and standardizing production protocols and performing stringent quality control (QC). The specific QC experiments performed vary between lentivirus particle lots.
Mycoplasma Creative Biogene routinely tests for mycoplasma contamination using a mycoplasma detection kit. Cell lines are maintained for approximately 20 passages before being discarded and replaced with a new vial of early passage cells. Approximately 2 weeks after thawing, cell culture supernatants are tested for mycoplasma contamination. Creative Biogene ensures that lentiviral products are free of mycoplasma contamination.
Purity Creative Biogene evaluates the level of impurities, such as residual host cell DNA or proteins, in prepared lentiviral vectors to ensure they meet quality standards.
Sterility The lentiviral samples were inoculated into cell culture medium for about 5 days and the growth of bacteria and fungi was tested. Creative Biogene ensures that the lentiviral products are free of microbial contamination.
Transducibility Upon requirement, Creative Biogene can perform in vitro or in vivo transduction assays to evaluate the ability of lentivirus to deliver genetic material into target cells, and assess gene expression and functional activities.
Proviral Identity Confirmation All Creative Biogene lentiviral vectors are confirmed to have correctly integrated provirus using PCR. This test involves transducing cells with serial dilutions of the lentiviral vector, harvesting the cells a few days later, and isolating genomic DNA. This DNA is then used as a template to amplify a portion of the expected lentiviral insert.
Quick Inquiry

Background

Publications

Q & A

Customer Reviews

For use in gene therapy, the lentiviral genome has been modified in several ways to maximize safety. These modifications have been divided into three iterations. In the current third-generation system, the components of the viral genome are divided into packaging plasmids, transfer plasmids, and envelope plasmids, which are primarily transfected into HEK 293T cells for virion production. The packaging plasmid contains all the elements required for viral production, including genes for the structural and enzymatic proteins gag and pol, as well as the viral regulatory gene rev. Alternatively, rev can also be expressed from a second packaging plasmid, resulting in a four-plasmid system. The transfer plasmid contains the transgene of interest as well as the necessary cis-acting elements, such as the psi(y) RNA packaging signal and the 3′ and modified 5′ LTR elements. This modified 5′ LTR replaces the endogenous HIV promoter with a constitutively active tat-independent promoter, allowing the tat gene to be deleted from the packaging plasmid. The env-encoded protein is expressed on a separate plasmid sequence and can be expressed by altering the tropism of the virus (a process called pseudotyping). This multi-plasmid system ensures that only the gene of interest and the cis-acting sequences are present in subsequent transductions. Nonessential viral proteins, such as accessory proteins, are completely deleted, which helps reduce immunogenicity, and the deletion of these coding sequences further reduces the likelihood of recombination, resulting in replication-competent lentivirus. Further safety improvements have been made in second- and third-generation systems, including the development of a self-inactivating transfer vector. This is achieved by deleting the U3 region of the 3′ LTR of the transfer vector, which is transferred to the 5′ LTR after reverse transcription and integration, effectively reducing the activity of the LTR promoter. This deletion does not significantly affect viral titers, and in addition, it reduces promoter interference, thereby avoiding unnecessary transgene silencing. The packaging of viral genes into separate plasmids and the use of self-inactivating transfer vectors further reduce the likelihood of generating replication-competent lentivirus.
Ask a Question

If your question is not addressed through these resources, you can fill out the online form below and we will answer your question as soon as possible.

Write a Review

Write a review of your use of Biogene products and services in your research. Your review can help your fellow researchers make informed purchasing decisions.

Needs improvement

Satisfaction

General satisfaction

Very satisfaction

CBpromise

Our promise to you:
Guaranteed product quality, expert customer support.

24x7 CUSTOMER SERVICE
CONTACT US TO ORDER